
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings is facing a potential decline in stock price following a reverse stock split scheduled for March 6, 2026, creating near-term trading pressure due to the perceived negative impact on the market. This makes it difficult for the company to maintain its position in the capital markets, resulting in a downgrade from Buy to Hold. The removal of the previous price target of $5.0 to $2.0 is reflective of this change in outlook.
Bears say
Tevogen Bio Holdings is facing multiple risk factors such as clinical/regulatory risk, partnership and financial risk, commercial risk, legal and intellectual property risk, and market share risk. The recent 50:1 reverse split will also likely disturb the existing shareholder base and reduce liquidity, ultimately creating more selling pressure. While the company's evaluation of a CRO acquisition signals progress, the declining share price will make it more difficult for the company to raise capital and potentially push out its timeline for commercialization to 2029.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares